The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .
The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .
Aged between 18 and 70 years old, regardless of gender;
Diagnosed as solid tumors by histopathology, and the tumor lesions could be detected or evaluated;
Be after standard treatment or who lack effective treatment programs;
Patients and their families were willing to participate in the clinical trial and signed the informed consent;
Any form of primary immunodeficiency disease (such as severe combined immunodeficiency disease);
Experiencing moderate to severe infection or possible opportunistic infection;
Patients with a history of autoimmunity (e.g., SLE, psoriasis, etc.);
Acute systemic infection, coagulation dysfunction or other serious cardiopulmonary diseases;
Guangzhou FineImmune Biotechnology Co., LTD.
Lead sponsor
Sun Yat-Sen University Cancer Center
Collaborator